Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan.
Mod Rheumatol
; 31(2): 408-416, 2021 Mar.
Article
em En
| MEDLINE
| ID: mdl-32615836
ABSTRACT
OBJECTIVES:
We examined the efficacy and safety of rituximab (RTX) maintenance therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in Japan.METHODS:
We conducted a retrospective study using a multi-center cohort database of vasculitis patients. All maintenance treatment courses were divided into three groups a RTX group, a group treated with other immunosuppressant drugs (IS) and a group receiving glucocorticoid monotherapy (GC). The primary endpoint was the comparison of relapse-free survival after 1 year. We also analyzed the occurrence of severe adverse events (SAEs) to assess safety.RESULTS:
We included 123 courses of 107 patients (RTX n = 14, IS n = 64, GC n = 45). Twelve of 14 in the RTX group patients were diagnosed with granulomatosis with polyangiitis (GPA). The relapse-free survival of RTX maintenance therapy was comparable to that in the other groups (p = .122). After 1 year of treatment, the RTX group was administered lower steroid doses and one-third of them could withdraw corticosteroid. The overall incidence of SAE was 0.54/patient-year in the RTX group, 0.39/patient-year in the IS group and 0.34/patient-year in the GC group.CONCLUSION:
RTX maintenance therapy could be effective and safe in Japanese GPA patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antirreumáticos
/
Rituximab
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Japão